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  What’s the best way to 
manage upper extremity venous 
thrombosis? 
 standard management is best: 
 Start with unfractionated heparin 
or low-molecular-weight heparin and fol-
low with long-term therapy with a vitamin 
K antagonist (strength of recommendation 
[SOR]: C, expert consensus and case re-
ports). Some evidence supports thrombo-
lytic therapy, placement of a superior vena 
cava fi lter, or surgical thrombectomy in 
selected patients (SOR: C, expert consen-
sus and case reports). Whether to remove 
venous catheters during initial treatment 
for catheter-induced venous thrombosis 
remains unclear, because limited stud-
ies address this issue specifi cally (SOR: 
C, expert consensus and case reports).
Evidence summary
Upper extremity venous thrombosis 
(UEVT)—which typically refers to thrombosis 
of the brachial, axillary, or subclavian veins—
accounts for approximately 10% of all cases of 
venous thromboembolism.1 UEVT can occur 
spontaneously (Paget-Schroetter syndrome) 
or develop as a complication of cancer or in-
dwelling medical devices (such as long-term 
central venous catheters). 
Although signifi cant evidence-based data 
exist on treatment of lower extremity venous 
thrombosis, no good-quality studies specifi cal-
ly address management of UEVT. Review of the 
current literature revealed several small studies 
that compared various treatment strategies. 
Thrombolytics may work better 
than anticoagulants in some patients
A small retrospective study randomized 20 pa-
tients with UEVT to either treatment with an-
ticoagulant therapy with heparin and warfarin 
(n=11) or thrombolytic therapy (n=9).2 After a 
mean follow-up period of 81.7 months for the 
anticoagulation group and 52.1 months for 
the thrombolytic group, 4 more patients in the 
thrombolytic group achieved complete clini-
cal recovery and vein patency than in the an-
ticoagulant group (P=.04). When patients who 
recovered completely were added to those 
who showed some clinical improvement, 89% 
of the thrombolytic therapy group had satis-
factory outcomes, compared with 36% of the 
anticoagulant group (P=.028). 
Another small retrospective study looked 
at 10 consecutive patients with UEVT who 
were treated with either anticoagulant thera-
py (n=6) or thrombolytics (n=4).3 Fifty percent 
of patients treated with anticoagulants expe-
rienced partial or complete improvement in 
symptoms, whereas 100% of patients treated 
with thrombolytics had partial or complete 
resolution of both symptoms and thrombi. 
Overall, both studies raise the possibil-
ity that thrombolytic therapy is more eff ec-
tive than anticoagulation therapy in certain 
patients. Th e studies evaluated only active 
patients, 23 to 58 years of age, who had no 
contraindications to thrombolytic therapy. 
Neither study reported data on long-term out-
comes such as recurrences, bleeding, or post-
thrombotic sequelae.
Surgery may avoid 
long-term anticoagulation 
Two case studies evaluated treatment of UEVT 
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Thrombolytic 
therapy, a vena 
cava fi lter, or 
surgery may 
benefi t some 
patients.
References
with thrombolytic therapy followed by various 
surgical interventions (angioplasty, thrombec-
tomy, decompression via fi rst rib resection or 
anterior scalenectomy, and venous bypass).4,5 
Th e fi rst study reported that 8 of 9 patients who 
underwent fi rst-rib resection and 1 of 2 who 
underwent scalenectomy were free of residual 
symptoms at follow-up (mean 2 years, range 
6 months to 5 years).4 All patients were treated 
with thrombolytics before surgery. 
Th e second study demonstrated that 50% 
of the patients treated with a surgical inter-
vention without thrombolysis had complete 
symptom relief, while the remaining 50% re-
ported relief from pain but still had occasional 
swelling.5 Although more invasive, surgery may 
eliminate the need for long-term anticoagula-
tion therapy and enable a more rapid return to 
normal activities.
Data on vena cava fi lters are limited
Data supporting superior vena cava Green-
fi eld fi lters to treat UEVT are extremely lim-
ited. Of 6 patients with contraindications to 
anticoagulation therapy who were treated 
with a Greenfi eld fi lter, none had clinical evi-
dence of pulmonary embolism at 14 months.6
Th e study reported no data regarding long-
term sequelae or eff ects of the UEVT on the 
patients’ upper extremity.6
When in doubt, 
don’t (necessarily) take it out
For patients with central venous catheter-relat-
ed deep vein thrombosis, taking out the cath-
eter as part of treatment is controversial and 
should depend on clinical symptoms, the rea-
son for the catheter, and duration of use, as well 
as physician judgment.7 No RCTs have studied 
the eff ects of catheter removal as part of initial 
treatment. Current guidelines recommend re-
moving the catheter from patients with persis-
tent symptoms who have failed anticoagulant 
or thrombolytic treatment.1
Recommendations 
Th e American College of Chest Physicians rec-
ommends therapeutic doses of intravenous 
unfractionated heparin, low-molecular-weight 
heparin, or fondaparinux for initial treat-
ment of UEVT, followed by at least 3 months 
of treatment with a vitamin K antagonist.1 Th e 
organization also suggests that surgical throm-
bectomy, superior vena caval fi lters, thrombo-
lytic therapy, or catheter extraction may benefi t 
selected patients.                    JFP
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